新辅助化疗联合腹腔镜微创手术治疗进展期胃癌的临床效果

Clinical effect of neoadjuvant chemotherapy combined with laparoscopic minimally invasive surgery on advanced gastric cancer

目的观察新辅助化疗联合腹腔镜微创手术治疗进展期胃癌的临床效果。方法选取2016年5月至2019年7月我院收治的进展期胃癌患者50例进行回顾性分析,按照治疗方式不同将其分为对照组(25例,腹腔镜微创手术治疗)和观察组(25例,新辅助化疗联合腹腔镜微创手术治疗)。比较两组的临床疗效、胃功能相关指标水平、血清肿瘤标志物水平及生活质量评分。结果观察组的治疗总有效率及胃癌控制率均显著高于对照组(P<0.05)。治疗后,两组患者PG-Ⅰ/PG-Ⅱ均升高,G-17、CEA、CA125水平均降低,且观察组优于对照组(P<0.05)。治疗后,两组QOL-C30各领域评分均有所改善,且观察组优于对照组(P<0.05)。结论奥沙利铂和替吉奥新辅助化疗联合腹腔镜微创手术治疗进展期胃癌,能够有效改善患者的胃功能指标和肿瘤标志物水平,提高其临床疗效和生活质量,值得临床推广应用。

Objective To observe the clinical effect of neoadjuvant chemotherapy combined with laparoscopic minimally invasive surgery on advanced gastric cancer.Methods Fifty patients with advanced gastric cancer admitted in our hospital from May 2016 to July 2019 were selected for retrospective analysis.According to different treatment methods,the patients were divided into control group(25 cases,laparoscopic minimally invasive surgery)and observation group(25 cases,neoadjuvant chemotherapy combined with laparoscopic minimally invasive surgery).The clinical efficacy,gastric function related indexes levels,serum tumor markers levels and quality of life scores were compared between the two groups.Results The total effective rate of treatment and control rate of gastric cancer in the observation group were significantly higher than those in the control group(P<0.05).After treatment,the PG-Ⅰ/PG-Ⅱincreased in the two groups,the levels of G-17,CEA and CA125 decreased in the two groups,and those in the observation group were better than the control group(P<0.05).After treatment,the QOL-C30 scores in all fields of the two groups improved,and those of the observation group were better than the control group(P<0.05).Conclusion Oxaliplatin and tegafur neoadjuvant chemotherapy combined with laparoscopic minimally invasive surgery for advanced gastric cancer can effectively improve the levels of gastric function indexes and tumor markers,the clinical efficacy and quality of life of patients,which is worthy of clinical promotion and application.